{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T19:49:37Z","timestamp":1692388177554},"reference-count":67,"publisher":"Frontiers Media SA","issue":"12","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transpl Int"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1111\/tri.12870","type":"journal-article","created":{"date-parts":[[2016,10,13]],"date-time":"2016-10-13T05:40:11Z","timestamp":1476337211000},"page":"1257-1265","source":"Crossref","is-referenced-by-count":11,"title":["Use of direct-acting agents for hepatitis C virus-positive kidney transplant candidates and kidney transplant recipients"],"prefix":"10.3389","volume":"29","author":[{"given":"Lionel","family":"Rostaing","sequence":"first","affiliation":[{"name":"Department of Nephrology and Organ Transplantation; CHU Rangueil; Toulouse France"},{"name":"INSERM U563, IFR-BMT; CHU Purpan; Toulouse France"},{"name":"Universit\u00e9 Paul Sabatier; Toulouse France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Alric","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Digestive Diseases; CHU Purpan; Toulouse France"},{"name":"UMR 152, IRD; Toulouse 3 University; Toulouse France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nassim","family":"Kamar","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paul Sabatier; Toulouse France"},{"name":"INSERM U858; CHU Rangueil & Purpan; Toulouse France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2016,11,23]]},"reference":[{"issue":"Suppl. 5","key":"10.1111\/tri.12870-BIB0001|tri12870-cit-0001","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.1016\/j.dld.2014.10.005","article-title":"Extrahepatic manifestations of chronic hepatitis C virus infection","volume":"46","author":"Cacoub","year":"2014","journal-title":"Dig Liver Dis"},{"key":"10.1111\/tri.12870-BIB0002|tri12870-cit-0002","first-page":"139","article-title":"Hepatitis C virus infection and glomerular disease","volume":"66","author":"Fabrizi","year":"2014","journal-title":"Minerva Urol Nefrol"},{"key":"10.1111\/tri.12870-BIB0003|tri12870-cit-0003","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1080\/08860220701460160","article-title":"Acute hepatitis C in patients receiving hemodialysis","volume":"29","author":"Griveas","year":"2007","journal-title":"Ren Fail"},{"key":"10.1111\/tri.12870-BIB0004|tri12870-cit-0004","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2147\/TCRM.S74282","article-title":"Management of chronic hepatitis C virus infection in patients with end-stage renal disease: a review","volume":"11","author":"Aguirre","year":"2015","journal-title":"Ther Clin Risk Manag"},{"key":"10.1111\/tri.12870-BIB0005|tri12870-cit-0005","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1159\/000117573","article-title":"Hepatitis C in hemodialysis patients: current global magnitude, natural history, diagnostic difficulties, and preventive measures","volume":"28","author":"Rahnavardi","year":"2008","journal-title":"Am J Nephrol"},{"key":"10.1111\/tri.12870-BIB0006|tri12870-cit-0006","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1111\/j.1365-2036.2004.02290.x","article-title":"Meta-analysis: effect of hepatitis C virus infection on mortality in dialysis","volume":"20","author":"Fabrizi","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/tri.12870-BIB0007|tri12870-cit-0007","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1111\/ajt.12835","article-title":"Hepatitis C virus infection and kidney transplantation in 2014: what's new?","volume":"14","author":"Baid-Agrawal","year":"2014","journal-title":"Am J Transplant"},{"key":"10.1111\/tri.12870-BIB0008|tri12870-cit-0008","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/00007890-199803150-00011","article-title":"Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients","volume":"65","author":"Legendre","year":"1998","journal-title":"Transplantation"},{"key":"10.1111\/tri.12870-BIB0009|tri12870-cit-0009","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/hep.510290123","article-title":"Impact of hepatitis B and C virus on kidney transplantation outcome","volume":"29","author":"Mathurin","year":"1999","journal-title":"Hepatology"},{"key":"10.1111\/tri.12870-BIB0010|tri12870-cit-0010","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1053\/j.ajkd.2003.09.018","article-title":"The impact of hepatitis C virus viremia on renal graft and patient survival: a 9-year prospective study","volume":"43","author":"Mahmoud","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/tri.12870-BIB0011|tri12870-cit-0011","first-page":"S1","volume":"109","author":"Kidney disease: improving global outcomes (KDIGO)","year":"2008","journal-title":"Kidney Int"},{"key":"10.1111\/tri.12870-BIB0012|tri12870-cit-0012","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1136\/gutjnl-2014-307080","article-title":"Peg-interferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomized trial","volume":"64","author":"Liu","year":"2015","journal-title":"Gut"},{"key":"10.1111\/tri.12870-BIB0013|tri12870-cit-0013","doi-asserted-by":"crossref","first-page":"729","DOI":"10.7326\/0003-4819-159-11-201312030-00005","article-title":"Pegylated interferon-\u03b12a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial","volume":"159","author":"Liu","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1111\/tri.12870-BIB0014|tri12870-cit-0014","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/00007890-199409150-00018","article-title":"Low-dose recombinant leukocyte interferon-alpha treatment of hepatitis C viral infection in renal transplant recipients. A pilot study","volume":"58","author":"Thervet","year":"1994","journal-title":"Transplantation"},{"key":"10.1111\/tri.12870-BIB0015|tri12870-cit-0015","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1097\/00007890-199505270-00012","article-title":"Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients","volume":"59","author":"Rostaing","year":"1995","journal-title":"Transplantation"},{"key":"10.1111\/tri.12870-BIB0016|tri12870-cit-0016","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S1473-3099(15)70050-2","article-title":"Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)","volume":"15","author":"Bourliere","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1111\/tri.12870-BIB0017|tri12870-cit-0017","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","article-title":"Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study","volume":"384","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"key":"10.1111\/tri.12870-BIB0018|tri12870-cit-0018","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1016\/S0140-6736(15)60159-3","article-title":"Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial","volume":"385","author":"Hezode","year":"2015","journal-title":"Lancet"},{"key":"10.1111\/tri.12870-BIB0019|tri12870-cit-0019","first-page":"189","volume":"63","author":"EASL recommendations on treatment of Hepatitis C 2015","year":"2015","journal-title":"J Hepatol"},{"key":"10.1111\/tri.12870-BIB0020|tri12870-cit-0020","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","article-title":"Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus","volume":"62","author":"AASLD\/IDSA HCV guidance panel","year":"2015","journal-title":"Hepatology"},{"key":"10.1111\/tri.12870-BIB0021|tri12870-cit-0021","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1016\/j.cgh.2016.07.001","article-title":"Safety and effectiveness of direct-acting antiviral agents for treatment of patients with chronic hepatitis C virus infection and cirrhosis","volume":"14","author":"Maan","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1111\/tri.12870-BIB0022|tri12870-cit-0022","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(14)61795-5","article-title":"Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial","volume":"385","author":"Lawitz","year":"2015","journal-title":"Lancet"},{"key":"10.1111\/tri.12870-BIB0023|tri12870-cit-0023","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1542-4758.2007.00181.x","article-title":"Hepatitis C virus infection in dialysis patients","volume":"11","author":"Su\u0142owicz","year":"2007","journal-title":"Hemodial Int"},{"key":"10.1111\/tri.12870-BIB0024|tri12870-cit-0024","first-page":"349","article-title":"Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study","volume":"S0140-673","author":"Roth","year":"2015","journal-title":"Lancet"},{"key":"10.1111\/tri.12870-BIB0025|tri12870-cit-0025","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/liv.13102","article-title":"Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function","volume":"36","author":"Saxena","year":"2016","journal-title":"Liver Int"},{"key":"10.1111\/tri.12870-BIB0026|tri12870-cit-0026","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/liv.13025","article-title":"Sofosbuvir and simeprevir in hepatitis C genotype 1-patients with end-stage renal disease on haemodialysis or GFR <30 ml\/min","volume":"36","author":"Nazario","year":"2016","journal-title":"Liver Int"},{"key":"10.1111\/tri.12870-BIB0027|tri12870-cit-0027","doi-asserted-by":"crossref","first-page":"924","DOI":"10.3109\/23744235.2015.1078908","article-title":"Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency","volume":"47","author":"Hundemer","year":"2015","journal-title":"Infect Dis (Lond)"},{"key":"10.1111\/tri.12870-BIB0028|tri12870-cit-0028","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jhep.2016.02.044","article-title":"Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C","volume":"65","author":"Desnoyer","year":"2016","journal-title":"J Hepatol"},{"key":"10.1111\/tri.12870-BIB0029|tri12870-cit-0029","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1111\/1744-9987.12407","article-title":"Effect and safety of daclatasvir-asunaprevir combination therapy for chronic hepatitis C virus genotype 1b-infected patients on hemodialysis","volume":"20","author":"Miyazaki","year":"2016","journal-title":"Ther Apher Dial"},{"key":"10.1111\/tri.12870-BIB0030|tri12870-cit-0030","doi-asserted-by":"crossref","first-page":"88","DOI":"10.12998\/wjcc.v4.i3.88","article-title":"Combination therapy with daclatasvir and asunaprevir for dialysis patients infected with hepatitis C virus","volume":"4","author":"Sato","year":"2016","journal-title":"World J Clin Cases"},{"key":"10.1111\/tri.12870-BIB0031|tri12870-cit-0031","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00535-016-1162-8","article-title":"Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C","volume":"51","author":"Suda","year":"2016","journal-title":"J Gastroenterol"},{"key":"10.1111\/tri.12870-BIB0032|tri12870-cit-0032","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/jvh.12553","article-title":"Pharmacokinetics, efficacy and safety of daclatasvir plus asunaprevir in dialysis patients with chronic hepatitis C: pilot study","volume":"23","author":"Kawakami","year":"2016","journal-title":"J Viral Hepat"},{"key":"10.1111\/tri.12870-BIB0033|tri12870-cit-0033","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1053\/j.gastro.2016.02.078","article-title":"Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease","volume":"150","author":"Pockros","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1111\/tri.12870-BIB0034|tri12870-cit-0034","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1097\/01.tp.0000238898.14393.c9","article-title":"Treatment of hepatitis C virus infection (HCV) after renal transplantation: implications for HCV-positive dialysis patients awaiting a kidney transplant","volume":"82","author":"Kamar","year":"2006","journal-title":"Transplantation"},{"key":"10.1111\/tri.12870-BIB0035|tri12870-cit-0035","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1093\/ndt\/gfm011","article-title":"Diabetes mellitus after kidney transplantation: a French multicentre observational study","volume":"22","author":"Kamar","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/tri.12870-BIB0036|tri12870-cit-0036","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1097\/01.ASN.0000012382.97168.E0","article-title":"Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus","volume":"13","author":"Bloom","year":"2002","journal-title":"J Am Soc Nephrol"},{"issue":"Suppl 6","key":"10.1111\/tri.12870-BIB0037|tri12870-cit-0037","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/ndt\/10.supp6.125","article-title":"Hepatitis C and renal transplantation: outcome of patients","volume":"10","author":"Morales","year":"1995","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/tri.12870-BIB0038|tri12870-cit-0038","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nrneph.2015.5","article-title":"Hepatitis C and its impact on renal transplantation","volume":"11","author":"Morales","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"10.1111\/tri.12870-BIB0039|tri12870-cit-0039","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/00041552-199711000-00001","article-title":"Glomerular diseases in patients with hepatitis C virus infection after renal transplantation","volume":"6","author":"Morales","year":"1997","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1111\/tri.12870-BIB0040|tri12870-cit-0040","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1097\/01.ASN.0000145896.16153.43","article-title":"Hepatitis C, acute humoral rejection, and renal allograft survival","volume":"15","author":"Forman","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/tri.12870-BIB0041|tri12870-cit-0041","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/ndt\/17.1.129","article-title":"Severe evolution of chronic hepatitis C in renal transplantation: a case control study","volume":"17","author":"Zylberberg","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/tri.12870-BIB0042|tri12870-cit-0042","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0272-6386(03)00423-2","article-title":"Evaluation of hepatitis B and hepatitis C virus-infected renal allograft recipients with liver biopsy and noninvasive parameters","volume":"42","author":"Fehr","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/tri.12870-BIB0043|tri12870-cit-0043","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1111\/j.1600-6143.2005.00918.x","article-title":"Natural history of hepatitis C virus-related liver fibrosis after renal transplantation","volume":"5","author":"Kamar","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1111\/tri.12870-BIB0044|tri12870-cit-0044","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S0272-6386(03)00422-0","article-title":"Long-term ribavirin therapy in hepatitis C virus-positive renal transplant patients: effects on renal function and liver histology","volume":"42","author":"Kamar","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/tri.12870-BIB0045|tri12870-cit-0045","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1097\/01.TP.0000128911.87538.AA","article-title":"Histopathologic efficacy of ribavirin monotherapy in kidney allograft recipients with chronic hepatitis C","volume":"78","author":"Fontaine","year":"2004","journal-title":"Transplantation"},{"key":"10.1111\/tri.12870-BIB0046|tri12870-cit-0046","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jcv.2003.10.001","article-title":"Amantadine therapy in renal transplant patients with hepatitis C virus infection","volume":"30","author":"Kamar","year":"2004","journal-title":"J Clin Virol"},{"key":"10.1111\/tri.12870-BIB0047|tri12870-cit-0047","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jcv.2007.02.006","article-title":"Combination therapy with ribavirin and amantadine in renal transplant patients with chronic hepatitis C virus infection is not superior to ribavirin alone","volume":"39","author":"Calanca","year":"2007","journal-title":"J Clin Virol"},{"key":"10.1111\/tri.12870-BIB0048|tri12870-cit-0048","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1097\/01.ASN.0000079613.81511.3C","article-title":"Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation","volume":"14","author":"Kamar","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/tri.12870-BIB0049|tri12870-cit-0049","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/j.1432-2277.2009.01025.x","article-title":"No evidence of occult hepatitis C virus (HCV) infection in serum of HCV antibody-positive HCV RNA-negative kidney-transplant patients","volume":"23","author":"Nicot","year":"2010","journal-title":"Transpl Int"},{"key":"10.1111\/tri.12870-BIB0050|tri12870-cit-0050","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1159\/000046646","article-title":"Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C","volume":"21","author":"Huraib","year":"2001","journal-title":"Am J Nephrol"},{"key":"10.1111\/tri.12870-BIB0051|tri12870-cit-0051","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1034\/j.1600-6143.2003.00057.x","article-title":"Pretransplant interferon prevents hepatitis C virus-associated glomerulonephritis in renal allografts by HCV-RNA Clearance","volume":"3","author":"Cruzado","year":"2003","journal-title":"Am J Transplant"},{"key":"10.1111\/tri.12870-BIB0052|tri12870-cit-0052","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"Sulkowski","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1111\/tri.12870-BIB0053|tri12870-cit-0053","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis","volume":"370","author":"Kowdley","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1111\/tri.12870-BIB0054|tri12870-cit-0054","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1111\/tri.12870-BIB0055|tri12870-cit-0055","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1111\/tri.12870-BIB0056|tri12870-cit-0056","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/hep.27681","article-title":"Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C following liver transplantation","volume":"61","author":"Forns","year":"2014","journal-title":"Hepatology"},{"key":"10.1111\/tri.12870-BIB0057|tri12870-cit-0057","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1053\/j.gastro.2014.10.001","article-title":"Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation","volume":"148","author":"Charlton","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1111\/tri.12870-BIB0058|tri12870-cit-0058","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1053\/j.gastro.2014.09.023","article-title":"Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study","volume":"148","author":"Curry","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1111\/tri.12870-BIB0059|tri12870-cit-0059","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1056\/NEJMoa1408921","article-title":"An interferon-free antiviral regimen for HCV after liver transplantation","volume":"371","author":"Kwo","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1111\/tri.12870-BIB0060|tri12870-cit-0060","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/tri.12428","article-title":"Successful treatment of fibrosing cholestatic hepatitis with pegylated interferon, ribavirin and sofosbuvir after a combined kidney-liver transplantation","volume":"28","author":"Delabaudiere","year":"2014","journal-title":"Transpl Int"},{"key":"10.1111\/tri.12870-BIB0061|tri12870-cit-0061","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1111\/ajt.13518","article-title":"Efficacy and safety of sofosbuvir-based anti-viral therapy to treat hepatitis C virus infection after kidney transplantation","volume":"16","author":"Kamar","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1111\/tri.12870-BIB0062|tri12870-cit-0062","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1111\/ajt.13620","article-title":"Successful treatment of hepatitis C in renal transplant recipients with direct-acting antiviral agents","volume":"16","author":"Sawinski","year":"2016","journal-title":"Am J Transplant"},{"key":"10.1111\/tri.12870-BIB0063|tri12870-cit-0063","doi-asserted-by":"crossref","first-page":"e0158431","DOI":"10.1371\/journal.pone.0158431","article-title":"Efficacy and safety of direct acting antivirals in kidney transplant recipients with chronic hepatitis C virus infection","volume":"11","author":"Lin","year":"2016","journal-title":"PLoS One"},{"key":"10.1111\/tri.12870-BIB0064|tri12870-cit-0064","doi-asserted-by":"crossref","first-page":"S183","DOI":"10.1016\/S0168-8278(16)00116-1","article-title":"Ledipasvir\/sofosbuvir for 12 or 24 weeks is safe and effective in kidney transplant recipients with chronic genotype 1 or 4 HCV infection","volume":"64","author":"Colombo","year":"2016","journal-title":"J Hepatol"},{"key":"10.1111\/tri.12870-BIB0065|tri12870-cit-0065","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000001336","article-title":"Successful posttransplant treatment of hepatitis C with ledipasvir-sofosbuvir in HIV+ kidney transplant recipients","author":"Sawinski","year":"2016","journal-title":"Transplantation"},{"key":"10.1111\/tri.12870-BIB0066|tri12870-cit-0066","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/j.1399-0012.2004.00256.x","article-title":"Cyclosporine pharmacokinetics in anti-HCV+ patients","volume":"18","author":"Wolffenbuttel","year":"2004","journal-title":"Clin Transplant"},{"key":"10.1111\/tri.12870-BIB0067|tri12870-cit-0067","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1097\/FTD.0000000000000315","article-title":"Pharmacokinetics of tacrolimus and cyclosporine in liver transplant recipients receiving 3 direct-acting antivirals as treatment for hepatitis C infection","volume":"38","author":"Badri","year":"2016","journal-title":"Ther Drug Monit"}],"container-title":["Transplant International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftri.12870","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftri.12870","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/tri.12870\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T18:39:31Z","timestamp":1641062371000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tri.12870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,23]]},"references-count":67,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"URL":"https:\/\/doi.org\/10.1111\/tri.12870","archive":["Portico"],"relation":{},"ISSN":["0934-0874"],"issn-type":[{"value":"0934-0874","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11,23]]}}}